Abstracts tagged "SLE"

Abstract Number: 2611 • 2017 ACR/ARHP Annual Meeting
Walk SLE – a Pilot Study Exploring Walk with Ease (WWE), a Self-Directed Walking Program, in Lupus Patients
Brittaney-Belle E. Gordon¹, Katherine Kaufman², Sean T. Hicks¹, Julie A. Norfleet¹, Rebecca J. Cleveland¹, Leigh F. Callahan³ and Saira Z. Sheikh¹, ¹Thurston Arthritis Research Center, University of North Carolina School of Medicine, Chapel Hill, NC, ²Department of Pediatrics, Duke University School of Medicine, Durham, NC, ³Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose: Fatigue and arthritis are common sources of impairment in SLE patients that persist despite lifestyle and pharmacologic interventions. Walk with Ease (WWE) is the…
Abstract Number: 706 • 2017 ACR/ARHP Annual Meeting
Elevated Erythrocyte Sedimentation Rate Among Obese Patients with SLE- Not Always a Marker of Disease Activity
George Stojan¹, Erik Barr² and Michelle Petri³, ¹Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD, ³Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD
Background/Purpose: Obesity is more common in patients with SLE compared to the general population. The prevalence of obesity among SLE patients is between 28 and…
Abstract Number: 1597 • 2017 ACR/ARHP Annual Meeting
Arthritis and Hydroxychloroquine Are Associated with Decreased Risk of Macrophage Activation Syndrome Among Adults Hospitalized with SLE
Kristin D'Silva¹, Ezra Cohen², David J. Kreps³, Mary Beth Son² and Karen H. Costenbader³, ¹Internal Medicine, Brigham and Women's Hospital, Boston, MA, ²Boston Children's Hospital, Boston, MA, ³Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Macrophage activation syndrome (MAS) is an uncommon but potentially fatal complication of SLE. We conducted a case-control study comparing hospitalized adults with SLE with…
Abstract Number: 1835 • 2017 ACR/ARHP Annual Meeting
Microglial Defects Contribute to Neuropsychiatric Symptoms of Systemic Lupus Erythematosus
Hadijat Makinde¹, Philip J. Homan², Harris Perlman² and Carla Cuda², ¹Northwestern University, Chicago, IL, ²Department of Medicine Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Neuropsychiatric symptoms of systemic lupus erythematosus (NP-SLE), including headaches, cognitive dysfunction and psychiatric disorders, appear in up to 75% of SLE patients and may…
Abstract Number: 2618 • 2017 ACR/ARHP Annual Meeting
Why Aren’t All Patients with SLE Taking Hydroxychloroquine? A Retrospective Chart Review
Caroline H. Siegel¹, Jennifer M. Grossman¹, John Fitzgerald¹, Bevra H. Hahn^1,2, Lori Sahakian¹, Eloise Olmos² and Maureen A. McMahon¹, ¹UCLA David Geffen School of Medicine, Los Angeles, CA, ²Division of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Although previous SLE treatment guidelines recommended judicious use of antimalarials, there is a growing body of evidence demonstrating that HCQ prevents flares, protects against…
Abstract Number: 708 • 2017 ACR/ARHP Annual Meeting
Anti-RNP/Sm Antibodies Plus Lupus Anticoagulant As Risk Factor for Thrombosis in Patients with Systemic Lupus Erythematosus
Mari Carmen Zamora-Medina¹, Andrea Hinojosa-Azaola², Carlos Núñez-Álvarez³ and Juanita Romero-Diaz⁴, ¹Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutricion S.Z., Mexico City, Mexico, ²Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion S.Z., Mexico city, Mexico, ⁴Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico city, Mexico
Background/Purpose: In a previous study, we identify a potential role of anti-RNP/Sm in combination with LA as risk factor for thrombosis. We aimed to validate…
Abstract Number: 1611 • 2017 ACR/ARHP Annual Meeting
Increased Body Mass Index May Not be a Risk Factor for the Development of Lupus Nephritis
Yu Pei Chock¹, Abhijeet Danve¹, Wei Fu² and Michelle Petri³, ¹Rheumatology, Yale University, New Haven, CT, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD
Background/Purpose: Studies have indicated that increased body mass index (BMI) is a risk factor for development of Chronic Kidney Disease (CKD). Obesity is a low…
Abstract Number: 1838 • 2017 ACR/ARHP Annual Meeting
Estimating Duration of Response in Systemic Lupus Erythematosus (SLE) Trials
Mimi Kim¹, Joan T. Merrill², Kenneth C. Kalunian³, Leslie Hanrahan⁴ and Peter M. Izmirly⁵, ¹Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Division of Rheumatology, Allergy and Immunology, UCSD School of Medicine, La Jolla, CA, ⁴Lupus Foundation of America, Washington DC, DC, ⁵Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: The primary endpoint in SLE trials is usually response to therapy at a landmark visit. However, during a trial, patients may alternate between response…
Abstract Number: 2632 • 2017 ACR/ARHP Annual Meeting
The Southern California Lupus Registry: I. Baseline Characteristics of Patients with Systemic Lupus Erythematosus in an Uncharted Territory
Joshua Liu¹, Kathleen Teves², Van La², Arlene Bravo³, Sheila Lezcano⁴, Talha Khawar⁴, Ebrahim Sadeghi⁴, Cong-Bin Wang⁵, Karina Torralba⁶, Howard Yang⁵ and Vaneet K. Sandhu⁷, ¹Internal Medicine, Loma Linda University Medical Center, Loma Linda, CA, ²Internal Medicine, University of California, Riverside, Riverside, CA, ³Internal Medicine, Loma Linda University, Loma Linda, CA, ⁴Rheumatology, Loma Linda University Medical Center, Loma Linda, CA, ⁵Loma Linda University Medical Center, Loma Linda, CA, ⁶Internal Medicine/Rheumatology, Loma Linda University, Loma Linda, CA, ⁷Division of Rheumatology, Loma Linda University, Loma Linda, CA
Background/Purpose: The Southern California Lupus Registry (SCOLR) is a population-based, longitudinal, multi-ethnic cohort of subjects with SLE directed toward studying health and healthcare disparities in…
Abstract Number: 722 • 2017 ACR/ARHP Annual Meeting
Differential Diagnosis of Autoimmune Diseases, Outlier Detection Plus Subgrouping in Clinical Trials By High Content Autoantibody Profiling
Peter Schulz-Knappe, Petra Budde and Hans-Dieter Zucht, Protagen AG, Dortmund, Germany
Background/Purpose: Early diagnosis as well as initiation of successful treatment are two big challenges in the management of patients with autoimmune diseases (AID). Overlap of…
Abstract Number: 1625 • 2017 ACR/ARHP Annual Meeting
Incidence and Outcomes of Venous Thromboembolism in Hospitalized Patients with Systemic Lupus Erythematosus: Results from Nationwide Inpatient Sample Database 2003-2011
Shweta Kishore¹, Varun Mittal², Shradha Ahuja³ and Vikas Majithia^1,4, ¹Division of Rheumatology, University of Mississippi, Jackson, MS, ²Division of Hematology and Oncology, Albert Einstein Healthcare Network, Philadelphia, PA, ³Division of Hospital Medicine, University of Mississippi, Jackson, MS, ⁴Jackson VA Medical Center and University of Mississippi, Jackson, MS
Background/Purpose: Venous thromboembolism (VTE) is a major cause of mortality and morbidity in hospitalized patients. Hospitalized patients with autoimmune disorders are particularly at risk of…
Abstract Number: 1917 • 2017 ACR/ARHP Annual Meeting
A Novel Type I Interferon Biomarker on B Cell Predicts with Disease Activity in SLE and Can be Measured By Cell Surface Tetherin (CD317)
Yasser M El-Sherbiny^1,2,3, Md Yuzaiful Md Yusof¹, Antonios Psarras¹, Elizabeth M.A. Hensor¹, Kumba Kabba¹, Alaa Mohamed^1,4, Miriam Wittmann⁵, Paul Emery^5,6 and Edward M Vital^1,5,7, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals, NHS Trust, Leeds, United Kingdom, ³Clinical Pathology dept., School of Medicine, Mansoura University, Mansoura, Egypt, ⁴Faculty of Medicine, Assiut University, Department of Rheumatology and Rehabilitation, Assiut, Egypt, ⁵NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁶University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ⁷University of Leeds, Leeds, United Kingdom
Background/Purpose: SLE is an IFN-I-mediated disease with dysregulated handling of self-nuclear antigens triggering anti-viral immune mechanisms. The level of IFN-I activity appears to stratify for…
Abstract Number: 2633 • 2017 ACR/ARHP Annual Meeting
Patients with Secondary Sjögren’s Syndrome to SLE Are Characterized By Typical Autoantibodies and a Pro-Inflammatory State
Marika Kvarnstrom¹, Guillermo Ruacho², Johanna Gustafsson³, Agneta Zickert⁴, Vilija Oke⁵, Johan Rönnelid⁶, Kerstin Elvin⁷, Iva Gunnarsson⁸ and Elisabet Svenungsson⁸, ¹Unit of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ²Department of Medicine, Unit of Rheumatology,, Stockholm, Sweden, ³Dep. of Medicine, Karolinska Institutet, Karolinska University Hospital, Unit of rheumatology,, Stockholm, Sweden, ⁴Department of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁵Department of Medicine, Rheumatology Unit, Department of Medicine Solna, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ⁶Department of Immunology Genetics and Pathology, Uppsala University, Uppsala, Sweden, ⁷Department of Clinical Immunology and Transfusion Medicine,, 4Unit of Clinical Immunology, Stockholm, Sweden, ⁸Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose :Sjögren´s syndrome occurs in isolation (primary Sjögren´s syndrome, pSS), but it is also often secondary (sSS) to, and sometimes difficult to delineate from, other…
Abstract Number: 829 • 2017 ACR/ARHP Annual Meeting
Unraveling Race and Social Context in Understanding Disparities in Lupus Mortality in the United States
Titilola Falasinnu¹, Yashaar Chaichian², Latha Palaniappan³ and Julia F Simard⁴, ¹Health Research and Policy, Stanford University, Stanford, CA, ²Medicine, Immunology & Rheumatology Division, Stanford School of Medicine, Stanford, CA, ³Stanford University Medical Center, General Medical Disciplines, Stanford, CA, ⁴Division of Epidemiology, Health Research and Policy Department, Stanford School of Medicine, Stanford, CA
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that is a source of significantly decreased life expectancy in the United States. Women and…
Abstract Number: 1628 • 2017 ACR/ARHP Annual Meeting
Atrial Fibrillation/Flutter Hospitalizations Among Patients with SLE and Diabetes Compared to the General U.S. Medicaid Population
Sarah Chen¹, Medha Barbhaiya², Michael A. Fischer³, Hongshu Guan⁴, Candace H. Feldman⁵, Brendan M. Everett⁶ and Karen H. Costenbader⁷, ¹Brigham and Women's Hospital, Boston, MA, ²Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Rheumatology, Brigham & Women's Hospital, Boston, MA, ⁶Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁷Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: SLE patients have increased cardiovascular disease (CVD) risk, including higher risk of stroke, compared to age- and sex-matched diabetes mellitus (DM) patients. Although DM…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].